← Leaderboards
James Jeffrey Mulchahey
Phase 2 Discovery, Inc.
$779,044
Attributed
$779,044
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$779,044 · 5
By mechanism
R43$679,044 · 4
R44$100,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Phase 2 Discovery, Inc.
Same institution · by research overlap
- Somasundar Prasad Gabbita$5,653,311
Others in their field
Top investigators on “Enzyme Linked Immunosorbent Assay”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,730,646
- Philip Louis Felgner · Gene Therapy Systems, Inc.$41,441,562
- Marianne Ward · Duke University$21,475,073
- Andrew B Norman · University Of Cincinnati$21,321,632
- Eric S. Orwoll · Oregon Health And Science University$20,906,524
- Andrew E. Levin · Immunetics, Inc.$20,730,152
Research focus
Enzyme Linked Immunosorbent AssayDrug Design /Synthesis /ProductionNeurotoxicologyBiomarkerTechnology /Technique DevelopmentAlcoholism /Alcohol AbuseChemical CleavageDosageDrug Screening /EvaluationHuman TissueLiver FailureNerve InjuryNervous System Disorder DiagnosisPharmacokineticsProteolysisStatistics /BiometryTau ProteinsWestern BlottingsLaboratory RatSertralineMelatoninMeningitisMicrotubule Associated ProteinSleep Disorders
Grant awards (6)
Safety and Pharmacokinetics of PD6735 in the Elderly$324,340
R43 · FY2005 · AG
Biomarker of Neurotoxicity in Meningitis$112,627
R43 · FY2002 · NS
Melatonin Analog for Sleep Disorders$100,000
R44 · FY2002 · MH
Biomarker of Neurotoxicity in Alcohol Abuse$134,710
R43 · FY2001 · AA
SSRI for Treating Depressed HIV Patients$107,366
R43 · FY2001 · MH
Biomarker of Neurotoxicity in Alcohol Abuse$1
R43 · FY2001 · AA